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Estrogens regulate numerous physiological processes through their binding to estrogen receptors (ER) of α and β-types. However, while activated ERα enhances cell proliferation, activated ERβ inhibits cell proliferation and induces apoptosis. Normal and malignant immune cells express both types of ER but predominantly ERβ [4] . This property has been successfully used to selectively inhibit growth and induce apoptosis in an in vivo model of lymphoma [5] . In this study, the Granta519 mantle cell lymphoma (MCL) cell line was engrafted s.c. into nude mice. Treatment of mice with diarylpropionitrile (DPN) led to the inhibition of tumor cell growth. The biological effects of DPN were mediated by the inhibition of BAFF (B-cell activating factor) and GBR7 (growth factor receptor-bound protein 7) survival factors, and VEGF (vascular endothelial growth factor or VEGF), an angiogenic factor.
According to the dependency of MCL cells with their TME, we suspected that MCL tumor cells-stroma interactions would not be the same for MCL cells engrafted s.c. or in their physiological niche. We engineered four cell lines: JeKo1-mCherry-Luc, Z138-Luc, REC1-GFPLuc and Granta519-GFP from their respective parental cell lines. Cells were then injected i.v.
into NOD-SCID IL2Rγnull (NSG) mice (n = 6). All animals recapitulated bona fide MCL disease.
Tumor cells having luciferase activity were detected by bioluminescence imaging (BLI) with a (Fig S1) . BLI examination indicated that tumor cells housed in hematopoietic organs (bone marrow, spleen) and, in some cases, in non-hematopoietic organs (liver, lung, kidney). The identity of tumor cells was verified at the time of mice euthanasia by cytometry analysis of CD20+ cells purified from infiltrated organs ( Table 1) .
We analyzed the expression of ERα and ERβ on a panel of MCL cells both at the mRNA and protein levels. ERα mRNAs were absent or very low in all cell lines (data not shown)
according to previous data [5] . In contrast, ERβ was expressed in all MCL cell lines (including GFP/mCherry/Luc expressing JeKo1, Granta519, REC1 and Z138 cells) tested although at various levels ( Fig 1A) . We next assessed in vivo the effects of both DPN and ERB-041 (or 2-
on MCL dissemination and growth. Z138-Luc or REC1-GFP-Luc cells were injected in NSG mice. The same day, mice were separated into three groups (n = 3) receiving: vehicle (0.01% DMSO), DPN or ERB-041 both at the concentration of 1 mg/kg. Drugs and vehicle were injected i.p. 5 days a week. BLI was recorded each week starting at day 7. Mice were euthanized at day 31 (Z138-Luc) or day 41 (REC1-GFP-Luc). As shown Fig 1B, DPN or ERB-041 treatments did not modify the engraftment properties of MCL tumor cells, since all mice were engrafted with luciferase-positive cells, or their homing, since infiltrated organs were the same among the different groups. Moreover, the number of CD45+ tumor cells in each organ was also similar between the three groups ( Fig S2) . In sharp contrast with published data [5] , ERβ agonists have no effects on tumor cells growth in this in vivo model. In vitro, although DPN was more active than ERB-041 and, Granta519 being the cell line with the highest sensitivity, we did not observed any dose-dependent effect of ERβ agonists on cell proliferation ( Fig S3) . One main action of DPN is to counteract migration and invasion [5] . We next tested the effect of ERB-041 and DPN on MCL cells in two in vitro assays : one dedicated to chemotaxis, the other one to invasion. Our data indicated clearly that ERB-041 and DPN had no inhibitory effects on migration ( Fig 1C and Fig S4A) or invasion (Fig S4B) .
Finally, since DPN was reported to inhibit VEGF synthesis [5] , we looked at the effects of DPN and ERB-041 on angiogenesis using the tube formation assay. As shown Fig 1D and Fig S5, the density of tubes was similar in the ERβ-and vehicle-targeted groups. ERβ agonists had no effect on the formation of structures resembling a microvasculature bed. We then measured VEGF synthesis in conditioned medium of cultured MCL cells treated with ERβ agonists or vehicle using ELISA ( Fig S2C, Fig 1E) . Our data confirmed that the quantity of VEGF secreted MCL tumor cells remained the same after DPN or ERB-041 treatments. likely bypassing the effect of the drugs [7] . Alternatively, the pharmacokinetics distribution of ERβ agonists may be different in the model described here and the one of Yakimchuk and colleagues [5] . A low concentration of ERβ agonists could be present in the physiologic niches such as the bone marrow explaining the lack of efficiency for the treatment. Finally, model, where the neovascularization is crucial to bring to the tumor nutriments and oxygen.
By contrast, hematopoietic organs are less dependent on neovascularization.
However, our in vitro experiments confirmed that, although ERβ are well-expressed in the MCL cell lines, ERβ agonists had no effect on proliferation, migration, invasion or VEGF production, emphasizing the in vivo results. Interestingly, we found previously that, although able to decrease multiple myeloma cell proliferation, ERβ agonists are inefficient in vivo [8] .
In conclusion, our results highlight a lack of effects of ERβ agonists as single agents in mice.
Nonetheless, as it has been described that estrogen play an important role in BCR pathway regulation [9] , consequently further investigations would be required to assess the efficacy F o r P e e r R e v i e w O n l y -GFP †  G1  23  1  57  45  7  9  no  G4  37  2  21  47  3 10 < 1 *, in the JeKo1-mCherry-Luc series, three mice were sacrificed at day 23. **, in the Z138-Luc series, three mice were sacrificed at day 30. ***, in the REC1-GFP-Luc series, three mice were sacrificed at day 33. †, in the Granta-GFP series, three mice died unexpectedly at day 17, two mice were sacrificed at the same day. At the time of euthanasia, indicated organs were collected; single-cell suspensions were prepared, then stained with IOTest® CD20-PE (phycoerythrin, IM1451, FL2) or the corresponding isotype control and analyzed on an Attune acoustic focusing cytometer (Thermo Fisher Scientific). The percentage of positive cells in each organ is indicated in the table. no, no signal; nd, not done. [2] . These interactions are responsible for a mechanism known as CAM-DR (cell adhesion-mediated drug resistance) [2] . This is why current therapies attempt to target both tumor cells and the tumor microenvironment (TME).
according to previous data [5] . In contrast, ERβ was expressed in all MCL cell lines (including GFP/mCherry/Luc expressing JeKo1, Granta519, REC1 and Z138 cells) tested although at various levels ( Fig 1A) . We next assessed in vivo the effects of both DPN and ERB-041 (or 2- although DPN was more active than ERB-041 and, Granta519 being the cell line with the highest sensitivity, we did not observed any dose-dependent effect of ERβ agonists on cell proliferation (Fig S3) . One main action of DPN is to counteract migration and invasion [5] . We next tested the effect of ERB-041 and DPN on MCL cells in two in vitro assays : one dedicated to chemotaxis, the other one to invasion. Our data indicated clearly that ERB-041 and DPN had no inhibitory effects on migration (Fig 1C and Fig S4A) or invasion (Fig S4B) .
Finally, since DPN was reported to inhibit VEGF synthesis [5] , we looked at the effects of DPN and ERB-041 on angiogenesis using the tube formation assay. As shown Fig 1D and Fig S5, the density of tubes was similar in the ERβ-and vehicle-targeted groups. ERβ agonists had no effect on the formation of structures resembling a microvasculature bed. We then measured VEGF synthesis in conditioned medium of cultured MCL cells treated with ERβ agonists or vehicle using ELISA (Fig S2C, Fig 1E) . Our data confirmed that the quantity of VEGF secreted MCL tumor cells remained the same after DPN or ERB-041 treatments. likely bypassing the effect of the drugs [7] . Alternatively, the pharmacokinetics distribution of ERβ agonists may be different in the model described here and the one of Yakimchuk and colleagues [5] . A low concentration of ERβ agonists could be present in the physiologic niches such as the bone marrow explaining the lack of efficiency for the treatment. Finally, model, where the neovascularization is crucial to bring to the tumor nutriments and oxygen.
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MCL cells engraftment in immunocompromised mice
In vivo experiments were conducted in accordance with the recommendations of EEC (86/609/CEE). They were approved by the Animal Experimental Ethics Committee of our institution (UB-CEEA agreement 251/15 in Spain). Z138-GFP-Luc, REC1-GFP-Luc, JeKo1-mCherry-Luc, Granta519-GFP cell lines were engineered using lentiviruses or retroviruses.
Male NSG (n = 6 per group) mice (age 6-8 weeks) were injected i.v. with 10 7 cells in a final volume of 100 μl. Tumor engraftment was determined weekly by bioluminescence imaging (BLI). Mice were injected i.p. with 75 mg/kg of D-luciferine and then analyzed with a Aequoria Luxiflux bioluminescent device quipped with an ORCA-ER camera (Hamamatsu).
Photon emissions were captured through the whole mouse body. At the end of the For ERβ agonists treatment, mice were either engrafted with Z138-Luc or REC1-GFP-Luc. The same day, mice were separated into three groups (n=3 in each one), one receiving DPN (1 mg/kg), another ERB-041 (1mg/kg), and the last one vehicle (0.1% DMSO). Mice were treated five days a week. Mice of the Z138 group were euthanized at day 29, of the REC1 group, at day 39. BLI was recorded as mentioned before.
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